Depression and Inflammation

[kim]

Thanks SFmom and this was a wonderful statement to read!

 

YES!!!! We are close to 100% but I won't feel confident posting that until we are COMPLETELY symptomless

[sf_mom]

Kim

 

The nutritionist we are working with helped a child diagnosed with TS.... child is 9 and now 100% symptomless. It took them several years but they got there on just her method of treatment, Bentonite Clay, High Dose Probiotics and High Dose B-12. BUT, she is also a believer in using the crutches 'antibiotics and IVIG' to help healing along.

 

-Wendy

 

 

 

Thanks SFmom and this was a wonderful statement to read!

 

YES!!!! We are close to 100% but I won't feel confident posting that until we are COMPLETELY symptomless

[kim]

From article Cheri originally posted

 

Concentrations of tumor necrosis factor-alpha (TNF-) and interleukin (IL)-6 were significantly higher in depressed patients than in controls.

from my reply

 

This article seems pretty relevant. Celery and green peppers!

 

http://www.dietaryfiberfood.com/antioxidan...antioxidant.php

 

 

Those cells that were also exposed to luteolin showed a significantly diminished inflammatory response. Jang showed that luteolin was shutting down production of a key cytokine in the inflammatory pathway, interleukin-6 (IL-6). The effects of luteolin exposure were dramatic, resulting in as much as a 90 percent drop in IL-6 production in the LPS-treated cells.

 

“This was just about as potent an inhibition as anything we had seen previously,” Johnson said.

 

and

 

 

To see if luteolin might have a similar effect in vivo, the researchers gave mice luteolin-laced drinking water for 21 days before injecting the mice with LPS.

 

Those mice that were fed luteolin had significantly lower levels of IL-6 in their blood plasma four hours after injection with the LPS. Luteolin also decreased LPS-induced transcription of IL-6 in the hippocampus, a brain region that is critical to spatial learning and memory.

I just came across this on the page for the "Presenters/Presentations" for the autism one 2010 conference

 

http://conference.autismone.org/abstracts.cfm?a1year=2010

 

 

"Allergic-like" symptoms, brain inflammation and autism: beneficial effect of a luteolin formulation (NeuroProtek®)

 

Children with ASD often present with “allergic” symptoms, including food allergies and food intolerance, but often without positive skin or blood RAST tests, suggesting mast cell activation by non-allergic triggers. Moreover, children with mastocytosis, a spectrum of diseases (www.tsmforacure.org) that present with skin allergies, diarrhea, learning disabilities, hyperactivity and difficulty focusing, reminiscent of ASD have a 10-fold higher prevalence of ASD (1/10) than the children reported for the general population. A number of papers have suggested that ASD may be associated with some immune dysfunction. However, only a few studies investigated biomarkers in ASD. We show that the peptide neurotensin (NT) is increased in the serum of children with autism. NT was originally isolated from the brain, but is present also in the gastrointestinal tract. NT can induce intestinal inflammation, stimulate lymphocyte proliferation, activate T cells, is also a potent trigger of mast cells, and acts synergistically with corticotropin-releasing hormone (CRH), secreted under stress, to induce mast cell-dependent disruption of the blood-brain barrier (BBB). This is relevant because ASD patients are prone to stress, and have serum auto-antibodies against brain proteins suggesting BBB disruption. We also show that, mercury induces mast cell secretion of vascular endothelial growth factor (VEGF), an action augmented by NT, suggesting that a subgroup of patients with activated mast cells may be more vulnerable to mercury. Finally, we show that the natural flavonoid luteolin, with anti-oxidant and anti-inflammatory actions, inhibits mast cell and T cell activation, as well as BBB permeability. Luteolin also inhibits IL-6 release from microglia cells, is neuroprotective for glia, can inhibit cytokine release from peripheral blood monocytes from multiple sclerosis patients, as well as autism-like behavior in mice. Finally, luteolin (5,7, 3’,4’-tetrahydroxyflavone) is closely related to 7,8-dixydroxyflavone recently shown to mimic brain-derived neurotrophic factor (BDNF), which is neuroprotective.

 

This is some info on the presenter

 

Theoharis Theoharides, MD, PhD

is a professor of pharmacology, Internal Medicine and Biochemistry, and the director of the Laboratory of Molecular Immunopharmacology and Drug Discovery; Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine. He trained in allergy and clinical immunology at Yale and internal medicine at New England Medical Center. Dr. Theoharides was director of medical pharmacology at Tufts (1986-1993), and became full professor in 1995. He has 300 publications and 3 books, including a Textbook of Pharmacology. Dr. Theoharides was the first to show mast cells and acute stress promote inflammation in autism, cancer, interstitial cystitis, migraines and multiple sclerosis.

 

I think there is a lot of info on the page that many would find interesting including Dr. T and Sammy's moms description of their presentations

[kim]

I was looking at anti inflamms this morning. Trying to find a luteolin supplement (can only stomach so much celery) and ran across this. Just more info on the IL-6 auto inflammatory process.

 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014821/?tool=pmcentrez

 

Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biological activities that plays an important role in immune regulation and inflammation. Among other actions, it induces terminal differentiation of B lymphocytes into antibody-forming cells and the differentiation of T cells into effector cells. IL-6 also has multiple potent proinflammatory effects. An association between IL-6 and lupus was demonstrated in murine models of SLE and blocking IL-6 improved lupus in all models tested. Data from several studies suggest that IL-6 plays a critical role in the B cell hyperactivity and immunopathology of human SLE, and may have a direct role in mediating tissue damage. Based on these data, we propose that blocking the effect of IL-6 in humans may improve lupus by interacting with the auto inflammatory process both systemically and locally.